Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study

PURPOSE: Androgen receptor splice variant 7 (AR-V7) results in a truncated receptor, which leads to ligand-independent constitutive activation that is not inhibited by anti-androgen therapies, including abiraterone or enzalutamide. Given that previous reports suggested that circulating tumor cell (C...

Descripción completa

Detalles Bibliográficos
Autores principales: Armstrong, Andrew J., Halabi, Susan, Luo, Jun, Nanus, David M., Giannakakou, Paraskevi, Szmulewitz, Russell Z., Danila, Daniel C., Healy, Patrick, Anand, Monika, Rothwell, Colin J., Rasmussen, Julia, Thornburg, Blair, Berry, William R., Wilder, Rhonda S., Lu, Changxue, Chen, Yan, Silberstein, John L., Kemeny, Gabor, Galletti, Giuseppe, Somarelli, Jason A., Gupta, Santosh, Gregory, Simon G., Scher, Howard I., Dittamore, Ryan, Tagawa, Scott T., Antonarakis, Emmanuel S., George, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494355/
https://www.ncbi.nlm.nih.gov/pubmed/30865549
http://dx.doi.org/10.1200/JCO.18.01731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494355/
https://www.ncbi.nlm.nih.gov/pubmed/30865549
http://dx.doi.org/10.1200/JCO.18.01731

Ejemplares similares